Mark up one more purchase for Roche this week. Pharmaceutical companies are looking for for biotech purchases and Roche is not wasting one moment this week. Arius fits right in with current ongoing cancer research. Who will be on the list tomorrow? BD
Roche announced this morning that it is paying $189 million to buy Canada's Arius Research, a move that will help beef up its portfolio of experimental therapies for cancer and inflammation. Shareholders controlling a majority of the company's shares have already signed off on the pact, which provides a 14.5 percent price premium over Tuesday's close.